Rapport Therapeutics(RAPP.US) Director Buys US$1.08 Million in Common Stock

$Rapport Therapeutics(RAPP.US)$ Director HEALY JAMES purchased 44,032 shares of common stock on Jul 1, 2024 at an average price of $24.518 for a total value of $1.08 million.Source: Announcement What

Moomoo NewsJul 3 20:44 ET

Stifel Starts Rapport at Buy, Cites Lead Drug Candidate RAP-219

Seeking AlphaJul 2 14:45 ET

TD Cowen Initiates Rapport Therapeutics(RAPP.US) With Buy Rating

TD Cowen analyst Joseph Thome initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 34.2% and a total average return of

Moomoo NewsJul 2 06:31 ET · Ratings

Rapport Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 50.09% Stifel → $35 Initiates Coverage On → Buy

BenzingaJul 2 05:53 ET

Express News | Rapport Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

ReutersJul 2 05:48 ET

Stifel Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35

Stifel analyst Paul Matteis initiates coverage on $Rapport Therapeutics(RAPP.US)$ with a buy rating, and sets the target price at $35.According to TipRanks data, the analyst has a success rate of 47.5

Moomoo NewsJul 2 05:31 ET · Ratings